Ascension closes AmSurg deal following FTC scrutiny

Ascension closes AmSurg deal following FTC scrutiny is a pharma and life sciences industry update from Healthcare Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Sydney Halleman · 2026-06-05

Regulators cleared the nonprofit’s $3.9 billion AmSurg acquisition — but with conditions.

Source: Healthcare Dive